Drug intelligence / Profile preview

SZ00121

Development stage: Unknown
Lead developer: Sarfez Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

**SZ00121** is a Sarfez Pharmaceuticals Phase 1 fixed-dose combination candidate for **heart failure with preserved ejection fraction** and **resistant hypertension**. The product combines an unspecified loop diuretic with an unspecified sodium-glucose cotransporter 2 inhibitor, aiming to enhance renal sodium and fluid removal while reducing renal glucose and sodium reabsorption through SGLT2 inhibition.

Targets

SGLT2 (Sodium-glucose cotransporter protein subunit 2)

Beyond the preview

Go deeper on SZ00121.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SZ00121.

Explore the full profile